Durvalumab + Radiation for Small Cell Lung Cancer
Trial Summary
What is the purpose of this trial?
This this study is for individuals who have treatment-naïve extensive-stage small cell lung cancer (small cell lung cancer that wont respond to treatment). Doctors leading this study hope to learn if combining durvalumab, carboplatin and etoposide with hyofractionated ablative radiation therapy (radiation focused on certain parts of the body) will help treat your cancer and improve how long you can live with extensive-stage small cell cancer without it getting worse (progression-free survival). Your participation in this research will last about 48 months. Durvalumab along with chemotherapy has been approved by the Food and Drug Administration (FDA) for the treatment of small cell lung cancer along with chemotherapy. This study is testing the addition of radiation to durvalumab and chemotherapy.
Will I have to stop taking my current medications?
The trial protocol does not specify if you need to stop taking your current medications. However, you cannot take other cancer treatments or immunosuppressive medications within 14 days before starting the trial.
What data supports the effectiveness of the treatment Durvalumab + Radiation for Small Cell Lung Cancer?
Research shows that adding durvalumab to chemotherapy (carboplatin and etoposide) significantly improves overall survival in patients with extensive-stage small-cell lung cancer compared to chemotherapy alone. This suggests that durvalumab is an effective addition to treatment for this type of lung cancer.12345
Is the combination of Durvalumab and chemotherapy safe for treating lung cancer?
What makes the drug combination of Durvalumab, Carboplatin, and Etoposide unique for treating small cell lung cancer?
This treatment is unique because it combines Durvalumab, an immune therapy that helps the body's immune system fight cancer, with chemotherapy drugs Carboplatin and Etoposide, and has shown to improve survival in patients with extensive-stage small cell lung cancer compared to chemotherapy alone.138910
Research Team
Christine M. Bestvina
Principal Investigator
University of Chicago - Comprehensive Cancer Center
Eligibility Criteria
This trial is for adults over 18 with newly diagnosed extensive-stage small cell lung cancer that hasn't been treated yet. Participants must have a life expectancy of at least 12 weeks, be able to perform daily activities (ECOG status 0-2), and have tumors suitable for focused radiation. They should not be pregnant or breastfeeding, agree to use contraception, and cannot have had previous treatments like chemotherapy or certain immunotherapies for lung cancer.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive up to four 21-day cycles of chemotherapy with carboplatin, etoposide, and durvalumab, with ablative radiation added during the second cycle
Maintenance
Participants continue to receive a fixed dose of durvalumab until disease progression, serious side effects, or withdrawal from the study
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Ablative Radiation
- Carboplatin
- Durvalumab
- Etoposide
Carboplatin is already approved in United States, European Union, Canada for the following indications:
- Ovarian cancer
- Testicular cancer
- Lung cancer
- Head and neck cancer
- Brain cancer
- Ovarian cancer
- Small cell lung cancer
- Ovarian cancer
- Small cell lung cancer
- Testicular cancer
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Chicago
Lead Sponsor